

For marketing purposes Swiss edition Data as at end-September 2024 ISIN: LU1240803988


# UBS Strategy Xtra Fund Yield USD

Performance Review

UBS (Lux) Strategy Xtra SICAV - Yield (USD) Q-dist



#### Performance (basis USD, net of fees)<sup>1</sup>



Past performance is not a reliable indicator of future results.

## Performance in % (net of fees)<sup>1</sup>

	•							
in %	2020	2021	2022	2023	2024	Sep.	5 years Ø	ð p.a. 5
					YTD <sup>2</sup>	2024		years
Fund (USD)	7.16	5.74	-10.47	7.55	7.85	1.12	20.73	3.84
The performance s	shown do	es not ta	ake accou	unt of an	y commis	ssions, e	entry or ex	it
charges.								

1 These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset

2 YTD: year-to-date (since beginning of the year)

Global stocks and major fixed income markets delivered positive returns once again in September as the Fed embarked on its widely expected rate-cutting cycle, joining other central banks worldwide in easing the rates environment. Meanwhile, gold continued to outperform.

### Monthly performance

In September the fund performed positively with 1.1%. Major global equity markets performed positively, with China leading the rally, whereas Swiss and UK equities lost ground. Most fixed income markets closed the month in positive territory too, despite concerns regarding economic growth.

### **YTD** performance

YTD as of the end of September, the fund has delivered a positive performance of 7.8%. Both equities and fixed income have contributed positively in 2024. On the equity side, global opportunity and high-dividend stocks are the largest contributors. Within fixed income, high-grade bonds and corporates, as well as emerging market (EM) government bonds, have been the main performance drivers. Alternative strategies such as hedge funds and risk parity have also paid off.

### **Performance contributors**

Both fixed income and equities contributed positively in September, with the biggest contribution coming from fixed income. In fixed income, corporate and USD high-grade bonds were the main contributors. With regard to equities, developed markets excluding Switzerland and EM stocks were the positive contributors in this asset class. Hedge funds also generated a significantly positive contribution.

### Performance detractors

Swiss equities were significant detractors in September.

For more information UBS Fund Infoline: 0800 899 899 Internet: www.ubs.com/funds Contact your client advisor

Portfolio management representatives

Sebastian Richner Roland Kramer Daniel Hammar

# UBS Strategy Xtra Fund Yield USD

### Current allocation by sub-asset class in %

	Current allocation
Liquidity	4
High grade bonds	17.0
USD inflation linked bonds	4.0
USD corporate bonds	15.0
EUR corporate bonds	0.0
USD high yield bonds	3.0
EUR high yield bonds	2.0
Emerging market sovereign bonds	6.8
Emerging market corporate bonds	3.2
Cash synth	0.3
Other fixed income	0.0
Bonds	51.3
Switzerland	2.0
United States	14.3
Eurozone	5.0
United Kingdom	3.0
Emerging markets	3.2
Japan	0.0
Canada	0.0
Australia	0.0
Sweden	-0.1
Hong Kong	-0.1
Singapore	0.1
Global	1.3
Equities	28.7
Hedge funds	11.0
Risk Parity	4.0
Commodity	1.0
Alternative Investments	16
Total	100
For illustrative purposes only. Current allocation may be ch	anged at any time without prior

For illustrative purposes only. Current allocation may be changed at any time without prior notice. The allocation is based on the model portfolio of the strategy. Due to implementation exceptions, actual exposures may deviate. Foreign currency risks are largely hedged against the reference currency.

### 10 largest equity positions (%)

	Fund
Microsoft Corp	0.78
Amazon.com Inc	0.75
Taiwan Semiconductor Manufacturing Co Ltd	0.47
Broadcom Inc	0.43
NVIDIA Corp	0.32
Koninklijke Philips NV	0.31
ServiceNow Inc	0.30
Alphabet Inc	0.28
Tencent Holdings Ltd	0.28
UnitedHealth Group Inc	0.27

# Current investment strategy

We maintained our overweights in EM and Australian government bonds at the expense of US high-grade and Italian government bonds. In addition, we opened a long position in US 5-year Treasuries at the expense of 30-year Treasuries and cash. On the equity side, we remain overweight in IT stocks versus global equities. We are maintaining our position in gold.

## Risks

The fund invests in bonds of varying credit quality, money market securities and equities on a global basis, and may therefore be subject to fluctuations in value. The fund may use derivatives which can reduce investment risk or give rise to additional risks (inter alia the counterparty risk). The value of a unit may fall below the purchase price. This requires an elevated risk tolerance and capacity. Every fund reveals specific risks, a description of these risks can be found in the prospectus.

### 5 largest bond issuers (%)

	Fund
United States Treasury Note/Bond	
United States Treasury Inflation Indexed Bonds	2.55
United States Treasury Inflation Indexed Bonds - When Issued	1.30
International Bank for Reconstruction & Development	0.84
European Investment Bank	0.49

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Information Document, Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 6 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on www.ubs.com/funds. Before investing in a product please read the latest prospectus and key information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the fund level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions' and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/am-glossary.